Get the Stockscreener App
22.05
7.35%
-1.75
After Hours:
22.05
Lyell Immunopharma Inc stock is traded at $22.05, with a volume of 89,058.
It is down -7.35% in the last 24 hours and down -2.61% over the past month.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
See More
Previous Close:
$23.80
Open:
$23.65
24h Volume:
89,058
Relative Volume:
0.85
Market Cap:
$468.43M
Revenue:
$41,000
Net Income/Loss:
$-325.66M
P/E Ratio:
-1.1255
EPS:
-19.5907
Net Cash Flow:
$-165.54M
1W Performance:
-4.17%
1M Performance:
-2.61%
6M Performance:
+81.48%
1Y Performance:
+57.50%
1-Day Range:
$21.80
$23.65
1-Week Range:
$21.80
$24.82
52-Week Range:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
22.05 | 505.61M | 41,000 | -325.66M | -165.54M | -19.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Lyell Immunopharma (LYEL) to Release Earnings on Tuesday - MarketBeat
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know - TipRanks
LYEL.O Technical Analysis & Stock Price Forecast - Intellectia AI
LYEL Technical Analysis & ETF Price Forecast - Intellectia AI
Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewswire
Cancer therapy developer Lyell to join three investor conferences in March - Stock Titan
What is the long term forecast for Lyell Immunopharma Inc. stockEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
How Lyell Immunopharma Inc. stock reacts to global recession fearsPortfolio Risk Report & Weekly Return Optimization Plans - mfd.ru
What’s the MACD signal for Lyell Immunopharma Inc.Portfolio Value Summary & Free Verified High Yield Trade Plans - mfd.ru
Is Lyell Immunopharma Inc. stock gaining market shareWeekly Trend Recap & Stock Market Timing Techniques - mfd.ru
Can Lyell Immunopharma Inc. stock beat market expectations this quarterJuly 2025 Movers & Reliable Intraday Trade Alerts - mfd.ru
Will Lyell Immunopharma Inc. stock deliver shareholder valueMarket Trend Review & Fast Gaining Stock Strategy Reports - mfd.ru
Aug Spikes: Will Lyell Immunopharma Inc benefit from rate cutsJuly 2025 Volume & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap DownHere's Why - MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Up 28.0% in January - MarketBeat
Can Lyell Immunopharma Inc. maintain sales growthJuly 2025 Outlook & Fast Moving Stock Trade Plans - mfd.ru
Institution Moves: Can Lyell Immunopharma Inc maintain sales growth2025 Retail Activity & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
LYEL Should I Buy - Intellectia AI
Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs - BioPharma Dive
Lyell Immunopharma (NASDAQ:LYEL) COO Stephen Hill Sells 1,236 Shares - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Insider Sells $39,084.69 in Stock - MarketBeat
Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) CEO Sells 7,455 Shares of Stock - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 7.3%Should You Buy? - MarketBeat
Lyell Immunopharma Announces Initiation Of Patient Dosing In First-Of-Its-Kind Phase 3 Car T-Cell Clinical Trial - TradingView
Lyell Immunopharma, Inc. (Lyell) announced that dosing has begun for patients with aggressive large B-cell lymphoma in a groundbreaking Phase 3 clinical trial. - Bitget
Inside the first head-to-head CAR T cancer trial testing Lyell’s ronde-cel - Stock Titan
Sentiment Review: Is Lyell Immunopharma Inc. stock gaining market shareJuly 2025 Selloffs & Smart Allocation Stock Reports - mfd.ru
Insider Selling: Lyell Immunopharma (NASDAQ:LYEL) CEO Sells 438 Shares of Stock - MarketBeat
Is Lyell Immunopharma Inc. stock trending bullishBreakout Watch & Daily Profit Maximizing Tips - mfd.ru
Lyell (LYEL) CEO Lynn Seely granted 155,000 options and sells shares for taxes - Stock Titan
Lyell Immunopharma (LYEL) grants CSO 50,000 options, small share sale - Stock Titan
Pullback Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Setups & Daily Profit Focused Screening - baoquankhu1.vn
How do insiders feel about American Express CompanyIPO Watch & Technical Analysis for Trade Confirmation - baoquankhu1.vn
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Significant Growth in Short Interest - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading 13.4% HigherWhat's Next? - MarketBeat
Earnings Beat: How volatile is Lyell Immunopharma Inc stock2025 Technical Patterns & Smart Allocation Stock Tips - baoquankhu1.vn
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - Defense World
Entry Recap: Will Lyell Immunopharma Inc benefit from rate cutsExit Point & AI Forecast for Swing Trade Picks - baoquankhu1.vn
EPS Watch: What is the long term forecast for Lyell Immunopharma Inc stockPrice Action & Advanced Technical Signal Analysis - baoquankhu1.vn
How rising interest rates impact Lyell Immunopharma Inc. stock2025 Major Catalysts & AI Optimized Trading Strategy Guides - Улправда
Will Lyell Immunopharma Inc. stock benefit from automation2025 Price Targets & Fast Entry Momentum Trade Alerts - ulpravda.ru
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4.6%Here's Why - MarketBeat
Should I hold or sell Lyell Immunopharma Inc. stock in 2025Market Profile Overview & Low Cost Wealth Investment - bollywoodhelpline.com
Lyell Immunopharma (NASDAQ:LYEL) Shares Up 4.2%Still a Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% – Should You Sell? - Defense World
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 6.7%Here's Why - MarketBeat
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL) - Defense World
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Yahoo Finance
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data (NASDAQ:LYEL) - Seeking Alpha
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):